{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Immunosuppressant+Regimen&page=2", "query": { "intervention": "Immunosuppressant Regimen", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 127, "total_pages": 13, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Immunosuppressant+Regimen&page=3&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Immunosuppressant+Regimen&page=1&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-09T00:02:27.901Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT03301350", "title": "Neoadjuvant Carbo/Paclitaxel Followed by Doxorubicin/Cyclophosphamide in Breast Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Breast Cancer", "Triple Negative Breast Cancer" ], "interventions": [ { "name": "Carboplatin", "type": "DRUG" }, { "name": "Paclitaxel", "type": "DRUG" }, { "name": "Doxorubicin", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Pegfilgrastim", "type": "DRUG" }, { "name": "Filgrastim", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Wisconsin, Madison", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "74 Years", "sex": "ALL", "summary": "18 Years to 74 Years" }, "enrollment_count": 29, "start_date": "2017-11-07", "completion_date": "2022-02-07", "has_results": true, "last_update_posted_date": "2026-02-13", "last_synced_at": "2026-10-09T00:02:27.901Z", "location_count": 6, "location_summary": "Rockford, Illinois • Madison, Wisconsin • Milwaukee, Wisconsin + 2 more", "locations": [ { "city": "Rockford", "state": "Illinois" }, { "city": "Madison", "state": "Wisconsin" }, { "city": "Milwaukee", "state": "Wisconsin" }, { "city": "Milwaukee", "state": "Wisconsin" }, { "city": "Waukesha", "state": "Wisconsin" } ], "official_url": "https://clinicaltrials.gov/study/NCT03301350" }, { "nct_id": "NCT01165762", "title": "Combined Blood Stem Cell and Kidney Transplant of One Haplotype Match Living Donor Pairs.", "overall_status": "UNKNOWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "ESRD" ], "interventions": [ { "name": "Immune Tolerance", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Everett Meyer", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "60 Years", "sex": "ALL", "summary": "18 Years to 60 Years" }, "enrollment_count": 25, "start_date": "2010-07-14", "completion_date": "2025-06-14", "has_results": false, "last_update_posted_date": "2023-06-18", "last_synced_at": "2026-10-09T00:02:27.901Z", "location_count": 2, "location_summary": "Stanford, California • Madison, Wisconsin", "locations": [ { "city": "Stanford", "state": "California" }, { "city": "Madison", "state": "Wisconsin" } ], "official_url": "https://clinicaltrials.gov/study/NCT01165762" }, { "nct_id": "NCT06552169", "title": "REgulatory T Cell Therapy to Achieve Immunosuppression REduction", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Kidney Transplantation" ], "interventions": [ { "name": "Arm 1: SOC (mTOR + CNI)", "type": "DRUG" }, { "name": "Arm 2A: TRACT/MONO mTOR", "type": "BIOLOGICAL" }, { "name": "Arm 2B: TRACT/MONO CNI", "type": "BIOLOGICAL" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "Singulera Therapeutics Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 34, "start_date": "2025-06-13", "completion_date": "2031-12", "has_results": false, "last_update_posted_date": "2026-04-27", "last_synced_at": "2026-10-09T00:02:27.901Z", "location_count": 3, "location_summary": "Phoenix, Arizona • Chicago, Illinois • Rochester, Minnesota", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Rochester", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT06552169" }, { "nct_id": "NCT01598987", "title": "Efficacy, Safety and Tolerability of Everolimus in Combination With Reduced Exposure Cyclosporine or Tacrolimus in Paediatric Liver Transplant Recipients.", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Renal Function", "Liver Transplant" ], "interventions": [ { "name": "Introduction of everolimus with reduced cyclosporine or tacrolimus dose, the earliest 1 month and the latest 6 months after liver transplantation.", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "1 Month", "maximum_age": "17 Years", "sex": "ALL", "summary": "1 Month to 17 Years" }, "enrollment_count": 56, "start_date": "2012-10", "completion_date": "2016-06", "has_results": true, "last_update_posted_date": "2017-05-16", "last_synced_at": "2026-10-09T00:02:27.901Z", "location_count": 9, "location_summary": "Los Angeles, California • New Haven, Connecticut • Chicago, Illinois + 6 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Chicago", "state": "Illinois" }, { "city": "St Louis", "state": "Missouri" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT01598987" }, { "nct_id": "NCT03657342", "title": "Efficacy + Safety of Liposome Cyclosporine A to Treat Bronchiolitis Obliterans Post Single Lung Transplant (BOSTON-1)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Bronchiolitis Obliterans", "Chronic Rejection of Lung Transplant", "Lung Transplant Rejection", "Lung Transplant; Complications", "Lung Transplant Failure and Rejection", "Chronic Lung Allograft Dysfunction" ], "interventions": [ { "name": "Liposomal Cyclosporine A", "type": "DRUG" }, { "name": "standard of care", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Zambon SpA", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 62, "start_date": "2019-03-26", "completion_date": "2024-04-16", "has_results": true, "last_update_posted_date": "2025-10-27", "last_synced_at": "2026-10-09T00:02:27.901Z", "location_count": 25, "location_summary": "Phoenix, Arizona • Los Angeles, California • Palo Alto, California + 16 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" }, { "city": "Palo Alto", "state": "California" }, { "city": "San Francisco", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03657342" }, { "nct_id": "NCT00859586", "title": "Mismatched Donor Lymphocyte Infusions for Relapsed Disease Following Allogeneic Stem Cell Transplantation", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Leukemia, Myeloid, Acute", "Leukemia, Lymphoblastic, Acute", "Leukemia, Myelocytic, Chronic" ], "interventions": [ { "name": "Miltenyi Magnetic cell sorter for CD3", "type": "DEVICE" } ], "intervention_types": [ "DEVICE" ], "sponsor": "National Heart, Lung, and Blood Institute (NHLBI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "8 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "8 Years to 75 Years" }, "enrollment_count": 8, "start_date": "2009-02", "completion_date": "2014-09", "has_results": true, "last_update_posted_date": "2020-10-27", "last_synced_at": "2026-10-09T00:02:27.901Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT00859586" }, { "nct_id": "NCT01860170", "title": "Post-Transplant Bortezomib and High Dose Cyclophosphamide as Graft-Versus-Host Disease (GVHD) Prophylaxis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Hematological Malignancy" ], "interventions": [ { "name": "Cohort 1-Bortezomib (Velcade ®)", "type": "DRUG" }, { "name": "Cohort 2-Bortezomib (Velcade ®)", "type": "DRUG" }, { "name": "Cohort 3-Bortezomib (Velcade ®)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Corewell Health West", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 28, "start_date": "2012-04", "completion_date": "2018-03", "has_results": true, "last_update_posted_date": "2023-06-02", "last_synced_at": "2026-10-09T00:02:27.901Z", "location_count": 1, "location_summary": "Grand Rapids, Michigan", "locations": [ { "city": "Grand Rapids", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT01860170" }, { "nct_id": "NCT00252655", "title": "Use of Sirolimus vs. Tacrolimus For African-American Renal Transplant Recipients", "overall_status": "UNKNOWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Kidney Transplantation" ], "interventions": [ { "name": "Rapamune and Prograf", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Wayne State University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 40, "start_date": "2004-01", "completion_date": "2009-06", "has_results": false, "last_update_posted_date": "2007-04-19", "last_synced_at": "2026-10-09T00:02:27.901Z", "location_count": 1, "location_summary": "Detroit, Michigan", "locations": [ { "city": "Detroit", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT00252655" }, { "nct_id": "NCT00350181", "title": "Sirolimus & Mycophenolate Mofetil as GVHD Prophylaxis in Myeloablative, Matched Related Donor HCT", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Leukemia", "Lymphoma, Non-Hodgkin", "Hematologic Diseases", "Acute GVHD" ], "interventions": [ { "name": "Sirolimus", "type": "DRUG" }, { "name": "MMF", "type": "DRUG" }, { "name": "BCNU", "type": "DRUG" }, { "name": "VP-16", "type": "DRUG" }, { "name": "CY", "type": "DRUG" }, { "name": "FTBI", "type": "DRUG" }, { "name": "BU", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Stanford University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "2 Years", "maximum_age": "60 Years", "sex": "ALL", "summary": "2 Years to 60 Years" }, "enrollment_count": 11, "start_date": "2006-08", "completion_date": "2010-04", "has_results": false, "last_update_posted_date": "2021-09-23", "last_synced_at": "2026-10-09T00:02:27.901Z", "location_count": 1, "location_summary": "Stanford, California", "locations": [ { "city": "Stanford", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00350181" }, { "nct_id": "NCT05975450", "title": "Subcutaneous Abatacept in Renal Transplant Recipients", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Kidney Transplant Recipient" ], "interventions": [ { "name": "Abatacept 125Mg/Ml Syringe", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Idelberto Badell", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "18 Years to 70 Years" }, "enrollment_count": 16, "start_date": "2023-08-02", "completion_date": "2025-02-14", "has_results": true, "last_update_posted_date": "2026-04-03", "last_synced_at": "2026-10-09T00:02:27.901Z", "location_count": 2, "location_summary": "Atlanta, Georgia", "locations": [ { "city": "Atlanta", "state": "Georgia" }, { "city": "Atlanta", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT05975450" } ] }